MTCO2P21

Across TCGA pan-cancer cohorts, MTCO2P21 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTCO2P21 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTCO2P21 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCO2P21 expression acts as an unfavorable survival marker.

MESO, GBM, and STAD are the cancer types where MTCO2P21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.099	0.487	<.001	54	view →
GBM	DFS	Tertile	All	0.061	0.246	<.001	27	view →
STAD	OS	Quartile	All	0.289	0.572	.007	15	view →
ESCA	OS	Quartile	IV	0.159	0.549	.045	12	view →
CHOL	OS	Tertile	II,III,IV	0.201	0.700	.036	9	view →
THCA	DFS	Tertile	IV	0.463	0.902	.022	9	view →
ACC	DFS	Tertile	All	0.121	0.633	.028	9	view →
KIRP	DFS	Tertile	All	0.354	0.683	.035	3	view →
LIHC	DFS	Tertile	All	0.413	0.569	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTCO2P21–MESO (DFS)

Open the MESO breakdown →